Skip to content

Descriptive Analysis of Gut Microbiome Alterations in Hyperoxaluric Patients

Descriptive Analysis of Gut Microbiome Alterations in Hyperoxaluric Patients

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02794649
Enrollment
60
Registered
2016-06-09
Start date
2016-06-30
Completion date
2018-06-30
Last updated
2017-09-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Oxalate, Primary Hyperoxaluria, Microbiome

Brief summary

To characterize the microbiome in 4 groups of subjects (primary hyperoxaluria type I (PH1), idiopathic CaOx stone, enteric hyperoxaluria (EH) and healthy participants) by comparing the number of species and diversity of the microbial populations and pathway for oxalate metabolism by paralleling the gene expression of enzymes involved in oxalate degradation by gut bacteria.

Detailed description

Kidney stones affect as much as 10% of the US population with the most common type of stones made of calcium oxalate. Calcium and oxalate are present in the urine and can bind to each other, and form calcium oxalate kidney stones. Oxalate is absorbed in the gut from the food that is eaten and is removed from the body through urination. Gut bacteria is thought to play a role in decreasing oxalate absorption in the gut and its levels in the urine. With this research we hope to learn about differences in the bacteria that live in the gut of different groups of participants who are likely to form kidney stones, as well as healthy individuals. We will study healthy people with no history of kidney stones, people with a history of calcium oxalate (CaOx) kidney stones, people with a genetic disease called primary hyperoxaluria type1 (PH1) that increases their chances to form calcium oxalate kidney stones and, people with enteric hyperoxaluria (EH) a disease in which individuals have short bowels due to surgery which lead them to get calcium oxalate kidney stones. Our research questions are: 1. How different is the gut bacteria between participants with the conditions that make them more likely to form kidney stones and healthy participants with no history of kidney stones? 2. Is there any difference in the function of the individual bacteria, Oxalobacter formigenes known to reduce oxalate, between healthy participants with no history kidney stones and participants with PH1?

Interventions

None listed

Sponsors

Mayo Clinic
CollaboratorOTHER
New York University
CollaboratorOTHER
VA New York Harbor Healthcare System
Lead SponsorFED

Study design

Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
Yes

Inclusion criteria

* Primary hyperoxaluria: Patients diagnosed with type I PH by genetic testing and part of the Rare Kidney Stone Consortium (RKSC) Primary hyperoxaluria registry * Enteric hyperoxaluria: Patients with Roux-en-Y-gastric-bypass * Idiopathic CaOx stone : History of passing or having surgically removed a calcium oxalate kidney stone within 5 years of recruitment * Healthy participants with no history of kidney or bowel disease

Exclusion criteria

* History of kidney or liver transplant * History of antibiotics use within 6 months of recruitment

Design outcomes

Primary

MeasureTime frameDescription
Differences in composition of the fecal microbiome as measured by 16S ribosomal ribonucleic acid (rRNA) sequencing and whole genome shotgun sequencing between the study groups.1 yearDiversity and abundance of operational taxonomic units (OTUs) between different groups of subjects will be tested. Data from shotgun sequencing and degenerate quantitative polymerase chain reactions (qPCRs) will yield comparative expressions of the oxalate metabolism genes between the groups.

Countries

United States

Contacts

Primary ContactLama Nazzal, MD
lama.nazzal@nyumc.org212-686-7500
Backup ContactJessica Baylor, BA
jessica.baylor@nyumc.org646-501-4159

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026